EAMs among Canadian patients with AS from the Rhumadata dataset; overall, and according to levels of treatment status, key clinical, and demographic characteristics
| N | Uveitis | IBD | Dactylitis | Enthesitis | Any EAM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | ||
| Overall | |||||||||||
| N | 14.7 | 5.8 | 4.3 | 9.0 | 28.4 | ||||||
| Males | 566 | 81 | 14.3 | 29 | 5.1 | 23 | 4.1 | 47 | 8.3 | 151 | 26.7 |
| Females | 378 | 58 | 15.3 | 26 | 6.9 | 18 | 4.8 | 38 | 10.1 | 117 | 31.0 |
| ≤40 years at cohort entry | 651 | 111 | 17.1 | 37 | 5.7 | 29 | 4.5 | 58 | 8.9 | 192 | 29.5 |
| >40 years at cohort entry | 293 | 28 | 9.6 | 18 | 6.1 | 12 | 4.1 | 27 | 9.2 | 76 | 25.9 |
| Missing AS severity | 166 | 12 | 7.2 | 7 | 4.2 | 2 | 1.2 | 3 | 1.8 | 21 | 12.7 |
| Mild AS (BASDAI <3.5) | 271 | 47 | 17.3 | 16 | 5.9 | 12 | 4.4 | 21 | 7.7 | 79 | 29.2 |
| Moderate AS (3.5 ≤ BASDAI <6.0) | 252 | 44 | 17.5 | 12 | 4.8 | 13 | 5.2 | 26 | 10.3 | 81 | 32.1 |
| Severe AS (BASDAI ≥6.0) | 255 | 36 | 14.1 | 20 | 7.8 | 14 | 5.5 | 35 | 13.7 | 87 | 34.1 |
| Anti-TNF naïve | 490 | 47 | 9.6 | 18 | 3.7 | 11 | 2.2 | 25 | 5.1 | 92 | 18.8 |
| Anti-TNF treated [no switching] | 286 | 51 | 17.8 | 21 | 7.3 | 15 | 5.2 | 28 | 9.8 | 97 | 33.9 |
| Anti-TNF treated [with switching] | 168 | 41 | 24.4 | 16 | 9.5 | 15 | 8.9 | 32 | 19.0 | 79 | 47.0 |